基质金属蛋白酶2对非小细胞肺癌术后生存率的影响

Effects of Matrix Metalloproteinase 2 on Survival Rate of Patients with Resected Non-small-cell Lung Cancer

目的研究基质金属蛋白酶2(MMP2)在非小细胞肺癌(NSCLC)组织中的表达与预后。方法用免疫组化技术测定83例NSCLC的MMP2表达,并以Kaplan-Meier曲线描述生存率,Cox单、多因素分析MMP2表达与生存率的关系。结果83例手术切除的非小细胞肺癌中,MMP2过表达者60例,非过表达者23例,过表达率为72.3%。MMP2的过表达与肿瘤类型、病理分级、性别、年龄、吸烟史无明显关系;MMP2在肿瘤组织的过表达率与淋巴结转移状态及临床分期有关(P<0.05);MMP2过表达者预后较非表达患者差,5年生存率分别为7.4%、18.5%,但差异无显著性意义(P>0.05)。结论MMP2对判断NSCLC预后有一定的参考价值,但是能否作为判断预后的一个独立指标有待进一步多中心研究。

Objective： To study the expression of matrix metalloproteinase 2 （MMP2） and its prognostic value in non-small-cell lung cancer （NSCLC） . Methods： MMP2 expression was determined in 83 patients with NSCLC by immunohistochemical technique. Survival curves were plotted according to the Kaplan-Meier estimates. Single and multiple factors analysis with Cox＇s model were performed to clarify the association between MMP2 and survival rate. Results： Of 83 patients with surgically treated NSCLC by immunobistocbemical technique, the overexpression and no overexpression of MMP2 were 60 and 23 patients respectively. The overexpression ratio of MMP2 was 72.3%. Their overexpressions were not related to tumor types, clinical stages, pathological grades, sex, age, and smoking history. The overexpression of MMP2 in cancer tissues were related to clinical stages and lymph node metastasis status （P〈0.05）. The prognosis of patients with MMP2 ovcrexpression was worse than that of the patients with no overexpression. The 5-year survival rate of overexpression and no overexpression of MMP2 were 7. 4% and 18.5% respectively. But there was no statistical significance （P〉0.05）. Conclusion： MMP2 has a reference value for the judgment of prognosis in the NSCLC. It is worthwhile to make an intensive multicenter study to see whether VEGF could be an independent prognostic indicator.